I want to preface this post with the fact that Pat

I want to preface this post with the fact that Patrick Cox’s newsletter at Agora in 2012 is what turned me onto CTIX which is now IPIX. At that time CTIX had K in a phase1 study and that was pretty much it. An investment in CTIX in 2012 was a very high-risk lottery ticket that K might someday be a treatment for cancer. Leo has taken what once was a very long shot 1 trick pony company and 5 years later advanced the science with 3 potential blockbuster drug platforms through multiple phase 2 trials that IMO will make many of us shareholders very wealthy. Leo has done this while carefully managing resources while minimizing outstanding share dilution. Remarkably IPIX’s share price at $1.02 today is only about 40 cents more than what I paid for my initial 10,000 shares back in 2012. I personally expect this discrepancy of risk/reward to change starting next week with B-OM results and then dramatically change when a partnership is announced.

While I am thankful to Patrick Cox for turning me onto CTIX, his track record on picking winning stocks has more misses than hits IMO. As IPIX’s science continues to advance through the FDA maze, shareholder risk continues to dramatically decrease. I have unloaded most of my other Cox recommendations over the past years and continually used those funds to add to my IPIX holdings. Cox left Agora 3 years or so and went to Mauldin where he again recommended CTIX. Cox has been relatively quiet in regards to IPIX over the past year or so and even his last week write up was not his typical pound-the-table, this-company-will change-the-world-buy. Below is a sample list of some of Cox’s recommendations which I am unfortunately too familiar with.

Biotime (BTX) The only other Cox stock that I still own and believe has huge upside due to West leadership and stem cell intellectual property.

Galectin (GALT) Has had a roller-coaster week and still has a shot at being a big winner in the NASH market.

Star Scientific (CIGX) Live 20 years longer and 20 times richer with Anatabine! OOPS

NanoViricides (NNVC) Every viral disease will be a thing of the past if they could ever start a phase 1 study.

Provectus Pharm (PVCT) Rose Bengal too good to be true? Yes it is. OOPS

Echo Therapeutics (ECTE) Cool product with a tough lesson in toxic financing and major dilution. OOPS

In summary I think Cox is a very smart guy and a wonderful story teller. Some of his picks will turn out to be big winners and I believe IPIX will be one of them. Most of Cox’s recommendations are frogs that will give you warts when you kiss them. I am more than happy to have suffered through some of the losers from above to have stubbornly ended up with a severely overweight position in IPIX. Cheers to all IPIX longs!